Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UMK57 is a small molecule allosteric agonist of the microtubule depolymerase KIF2C (Kinesin Family Member 2C), also known as Mitotic Centromere-Associated Kinesin (MCAK). It functions by increasing the catalytic activity of KIF2C, which promotes the destabilization and correction of erroneous, hyperstable microtubule-kinetochore attachments during mitosis. In the context of reproductive medicine, UMK57 is being researched for its ability to reduce chromosome segregation errors and mosaic aneuploidy during the first mitotic division of human embryos. By improving mitotic fidelity, UMK57 may prevent pre-implantation embryo arrest and improve the efficiency of in vitro fertilization (IVF) procedures.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on UMK57.